WO2012059932A1 - Dérivés de 2,4-diaminopyrimidine en tant qu'inhibiteurs de protéine kinases - Google Patents

Dérivés de 2,4-diaminopyrimidine en tant qu'inhibiteurs de protéine kinases Download PDF

Info

Publication number
WO2012059932A1
WO2012059932A1 PCT/IN2010/000718 IN2010000718W WO2012059932A1 WO 2012059932 A1 WO2012059932 A1 WO 2012059932A1 IN 2010000718 W IN2010000718 W IN 2010000718W WO 2012059932 A1 WO2012059932 A1 WO 2012059932A1
Authority
WO
WIPO (PCT)
Prior art keywords
alkyl
formula
compound
nitro
cycloalkyl
Prior art date
Application number
PCT/IN2010/000718
Other languages
English (en)
Inventor
Saumitra Sengupta
Srinivasan Rajagopalan
Ningaraddi Belavagi
Muralidhara Ramachandra
Original Assignee
Aurigene Discovery Technologies Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aurigene Discovery Technologies Limited filed Critical Aurigene Discovery Technologies Limited
Priority to PCT/IN2010/000718 priority Critical patent/WO2012059932A1/fr
Publication of WO2012059932A1 publication Critical patent/WO2012059932A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48—Two nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/645—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having two nitrogen atoms as the only ring hetero atoms
    • C07F9/6509—Six-membered rings
    • C07F9/6512—Six-membered rings having the nitrogen atoms in positions 1 and 3

Abstract

La présente invention concerne de nouveaux dérivés de pyrimidine de formule (I) : pouvant être employés en tant qu'inhibiteurs de kinases. Plus particulièrement, la présente invention concerne de nouveaux composés de type pyrimidine, leurs méthodes de synthèse, les compositions pharmaceutiques les incluant et leur utilisation dans le traitement de troubles prolifératifs.
PCT/IN2010/000718 2010-11-01 2010-11-01 Dérivés de 2,4-diaminopyrimidine en tant qu'inhibiteurs de protéine kinases WO2012059932A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
PCT/IN2010/000718 WO2012059932A1 (fr) 2010-11-01 2010-11-01 Dérivés de 2,4-diaminopyrimidine en tant qu'inhibiteurs de protéine kinases

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/IN2010/000718 WO2012059932A1 (fr) 2010-11-01 2010-11-01 Dérivés de 2,4-diaminopyrimidine en tant qu'inhibiteurs de protéine kinases

Publications (1)

Publication Number Publication Date
WO2012059932A1 true WO2012059932A1 (fr) 2012-05-10

Family

ID=44367304

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IN2010/000718 WO2012059932A1 (fr) 2010-11-01 2010-11-01 Dérivés de 2,4-diaminopyrimidine en tant qu'inhibiteurs de protéine kinases

Country Status (1)

Country Link
WO (1) WO2012059932A1 (fr)

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8314119B2 (en) 2006-11-06 2012-11-20 Abbvie Inc. Azaadamantane derivatives and methods of use
CN103232397A (zh) * 2013-04-28 2013-08-07 江苏双乐化工颜料有限公司 5-氨基-n-取代苯并咪唑酮的合成方法
WO2015123595A1 (fr) 2014-02-14 2015-08-20 The Regents Of The University Of California Peroxydes cycliques utilisés en tant que promédicaments pour l'administration sélective d'agents
US9464078B2 (en) 2010-09-23 2016-10-11 Abbvie Inc. Monohydrate of azaadamantane derivatives
JP2017510644A (ja) * 2014-03-28 2017-04-13 キャリター・サイエンシーズ・リミテッド・ライアビリティ・カンパニーＣａｌｉｔｏｒ Ｓｃｉｅｎｃｅｓ， Ｌｌｃ 置換されたヘテロアリール化合物および使用方法
WO2017162661A1 (fr) 2016-03-22 2017-09-28 Bayer Pharma Aktiengesellschaft 1h-benzo[de]isoquinoléine-1,3(2h)-diones
US9932344B2 (en) 2014-02-21 2018-04-03 Cancer Research Technology Limited Pyrazolo[1,5-A]pyrimidine-5,7-diamine compounds as CDK inhibitors and their therapeutic use
CN109096152A (zh) * 2018-07-31 2018-12-28 乐平市赛复乐医药化工有限公司 一种间甲磺酰胺基苯胺的制备方法
US11857552B2 (en) 2017-09-20 2024-01-02 Carrick Therapeutics Limited 4-[[(7-aminopyrazolo[1,5-a]pyrimidin-5-yl)amino]methyl]piperidin-3-ol compounds as CDK inhibitors

Citations (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4166452A (en) 1976-05-03 1979-09-04 Generales Constantine D J Jr Apparatus for testing human responses to stimuli
US4256108A (en) 1977-04-07 1981-03-17 Alza Corporation Microporous-semipermeable laminated osmotic system
US4265874A (en) 1980-04-25 1981-05-05 Alza Corporation Method of delivering drug with aid of effervescent activity generated in environment of use
WO2002022608A1 (fr) 2000-09-15 2002-03-21 Vertex Pharmaceuticals Incorporated Composes pyrazole utiles comme inhibiteurs de la proteine kinase
WO2002050066A2 (fr) 2000-12-21 2002-06-27 Vertex Pharmaceuticals Incorporated Composes de pyrazole utiles comme inhibiteurs de proteines kinases
WO2004000833A1 (fr) 2002-06-20 2003-12-31 Vertex Pharmaceuticals Incorporated Procedes pour la preparation de pyrimidines substituees et derives de pyrimidines utilises comme inhibiteurs des proteine-kinases
WO2005118544A2 (fr) 2004-05-18 2005-12-15 Rigel Pharmaceuticals, Inc. Composes pyrimidinediamines a substitution cycloalkyle et leurs utilisations
WO2006010915A1 (fr) 2004-07-27 2006-02-02 Prometic Biosciences Limited Triazines substitues utilises comme ligands des proteines prions, et leur utilisation pour la detection ou l'extraction des prions
WO2006091737A1 (fr) 2005-02-24 2006-08-31 Kemia, Inc. Modulateurs de l'activite de gsk-3
WO2006136442A1 (fr) 2005-06-23 2006-12-28 Novartis Ag Derives de pyrimidine pour le traitement des troubles du systeme nerveux provoques par les gaba b
WO2007073117A1 (fr) 2005-12-22 2007-06-28 Crystalgenomics, Inc. Derives d'aminopyrimidine inhibiteurs de l'activite de la proteine kinase, son procede de preparation et composition pharmaceutique en contenant
US7250417B2 (en) 2003-07-02 2007-07-31 Sugen Inc. Arylmethyl triazolo- and imidazopyrazines as c-Met inhibitors
WO2007132010A1 (fr) * 2006-05-15 2007-11-22 Boehringer Ingelheim International Gmbh 2, 4 -diamino pyrimidine en tant qu'inhibiteurs de kinases du cycle cellulaire
WO2010024430A1 (fr) * 2008-09-01 2010-03-04 アステラス製薬株式会社 Composé 2,4-diaminopyrimidine

Patent Citations (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4166452A (en) 1976-05-03 1979-09-04 Generales Constantine D J Jr Apparatus for testing human responses to stimuli
US4256108A (en) 1977-04-07 1981-03-17 Alza Corporation Microporous-semipermeable laminated osmotic system
US4265874A (en) 1980-04-25 1981-05-05 Alza Corporation Method of delivering drug with aid of effervescent activity generated in environment of use
WO2002022608A1 (fr) 2000-09-15 2002-03-21 Vertex Pharmaceuticals Incorporated Composes pyrazole utiles comme inhibiteurs de la proteine kinase
WO2002022607A1 (fr) 2000-09-15 2002-03-21 Vertex Pharmaceuticals Incorporated Composes pyrazole utiles en tant qu'inhibiteurs de proteine kinase
WO2002022604A1 (fr) 2000-09-15 2002-03-21 Vertex Pharmaceuticals Incorporated Composes de pyrazole utiles comme inhibiteurs de proteine kinase
WO2002022603A1 (fr) 2000-09-15 2002-03-21 Vertex Pharmaceuticals Incorporated Composes de pyrazole pouvant etre utilises comme inhibiteurs de la proteine kinase
WO2002022601A1 (fr) 2000-09-15 2002-03-21 Vertex Pharmaceuticals Incorporated Composes pyrazoliques utiles comme inhibiteurs de la proteine kinase
WO2002022605A1 (fr) 2000-09-15 2002-03-21 Vertex Pharmaceuticals Incorporated Composes de pyrazole utiles comme inhibiteurs de proteine kinase
WO2002022602A2 (fr) 2000-09-15 2002-03-21 Vertex Pharmaceuticals Incorporated Composes de triazole, inhibiteurs de la proteine kinase
WO2002022606A1 (fr) 2000-09-15 2002-03-21 Vertex Pharmaceuticals Incorporated Composes a base de pyrazole pouvant etre utilises comme inhibiteurs de la proteine kinase
WO2002050065A2 (fr) 2000-12-21 2002-06-27 Vertex Pharmaceuticals Incorporated Composes de pyrazole presentant une grande utilite comme inhibiteurs de proteine kinase
WO2002057259A2 (fr) 2000-12-21 2002-07-25 Vertex Pharmaceuticals Incorporated Composes de pyrazole utiles en tant qu'inhibiteurs de proteine kinase
WO2002059111A2 (fr) 2000-12-21 2002-08-01 Vertex Pharmaceuticals Incorporated Composes de pyrazole utiles en tant qu'inhibiteurs de proteine kinase
WO2002059112A2 (fr) 2000-12-21 2002-08-01 Vertex Pharmaceuticals Incorporated Composes de pyrazole utiles en tant qu'inhibiteurs de la proteine kinase
WO2002062789A1 (fr) 2000-12-21 2002-08-15 Vertex Pharmaceuticals Incorporated Composes de pyrazole utiles comme inhibiteurs de proteines kinases
WO2002050066A2 (fr) 2000-12-21 2002-06-27 Vertex Pharmaceuticals Incorporated Composes de pyrazole utiles comme inhibiteurs de proteines kinases
WO2004000833A1 (fr) 2002-06-20 2003-12-31 Vertex Pharmaceuticals Incorporated Procedes pour la preparation de pyrimidines substituees et derives de pyrimidines utilises comme inhibiteurs des proteine-kinases
US7250417B2 (en) 2003-07-02 2007-07-31 Sugen Inc. Arylmethyl triazolo- and imidazopyrazines as c-Met inhibitors
WO2005118544A2 (fr) 2004-05-18 2005-12-15 Rigel Pharmaceuticals, Inc. Composes pyrimidinediamines a substitution cycloalkyle et leurs utilisations
WO2006010915A1 (fr) 2004-07-27 2006-02-02 Prometic Biosciences Limited Triazines substitues utilises comme ligands des proteines prions, et leur utilisation pour la detection ou l'extraction des prions
WO2006091737A1 (fr) 2005-02-24 2006-08-31 Kemia, Inc. Modulateurs de l'activite de gsk-3
WO2006136442A1 (fr) 2005-06-23 2006-12-28 Novartis Ag Derives de pyrimidine pour le traitement des troubles du systeme nerveux provoques par les gaba b
WO2007073117A1 (fr) 2005-12-22 2007-06-28 Crystalgenomics, Inc. Derives d'aminopyrimidine inhibiteurs de l'activite de la proteine kinase, son procede de preparation et composition pharmaceutique en contenant
WO2007132010A1 (fr) * 2006-05-15 2007-11-22 Boehringer Ingelheim International Gmbh 2, 4 -diamino pyrimidine en tant qu'inhibiteurs de kinases du cycle cellulaire
WO2010024430A1 (fr) * 2008-09-01 2010-03-04 アステラス製薬株式会社 Composé 2,4-diaminopyrimidine
EP2325175A1 (fr) * 2008-09-01 2011-05-25 Astellas Pharma Inc. Composé 2,4-diaminopyrimidine

Non-Patent Citations (18)

* Cited by examiner, † Cited by third party
Title
CARVAJAL RD ET AL., CLIN. CANCER RES., vol. 12, no. 23, 2006, pages 6869 - 75
CRISSMAN HA; STEINKAMP JA.: "Rapid simultaneous measurement of DNA, protein and cell volume in single cells from large mammalian cell populations", J. CELL BIOL., vol. 59, 1973, pages 766
FRANK, MOLT MED., vol. 5, 1999, pages 432 - 456
GARCIA- BUSTOS ET AL., EMBO J, vol. 13, 1994, pages 2352 - 2361
HANKS, S .K; HUNTER, T., FASEB J ., vol. 9, 1995, pages 576 - 596
HARDIE,G .; HANKS, S.: "The Protein Kinase Facts Book, I and II", 1995, ACADEMIC PRESS
HILES ET AL., CELL, vol. 70, 1992, pages 419 - 429
KIM NASMYTH, SCIENCE, vol. 21A, 1996, pages 1643 - 1677
KNIGHTON ET AL., SCIENCE, vol. 253, 1991, pages 407 - 414
KRISHAN A: "Rapid flow cytoflucrometric analysis of cell cycle by propidium lodide staining", J. CELL BIOL., vol. 66, 1975, pages 188
KUNZ ET AL., CELL, vol. 73, 1993, pages 585 - 596
LATOUR; VEILLETTE, CURR. OPIN. IMMUNOL., vol. 13, 2001, pages 299306
MAZEN W KARAMAN; SANNA HERRGARD ET AL., NAT BIOTECH
MOHAMMAD ET AL., EMBO JOURNAL, vol. 17, 1998, pages 5996 - 5904
SCHLESSINGER, CELL, vol. 100, 2000, pages 293 - 296
SEIDEL ET AL., ONCOGENE, vol. 19, pages 2645 - 2656
WEBSTER, EXP. OPIN. INVEST. DRUGS, vol. 1, 1998, pages 865 - 887
YOSHIJI. ET AL., CANCER RESEARCH, vol. 57, 1997, pages 3924 - 3928

Cited By (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8987453B2 (en) 2006-11-06 2015-03-24 Abbvie Inc. Azaadamantane derivatives and methods of use
US8314119B2 (en) 2006-11-06 2012-11-20 Abbvie Inc. Azaadamantane derivatives and methods of use
US9464078B2 (en) 2010-09-23 2016-10-11 Abbvie Inc. Monohydrate of azaadamantane derivatives
CN103232397A (zh) * 2013-04-28 2013-08-07 江苏双乐化工颜料有限公司 5-氨基-n-取代苯并咪唑酮的合成方法
CN103232397B (zh) * 2013-04-28 2016-04-20 江苏双乐化工颜料有限公司 5-氨基-n-取代苯并咪唑酮的合成方法
US10662215B2 (en) 2014-02-14 2020-05-26 The Regents Of The University Of California Cyclic peroxides as prodrugs for selective delivery of agents
US10287312B2 (en) 2014-02-14 2019-05-14 The Regents Of The University Of California Cyclic peroxides as prodrugs for selective delivery of agents
US11014955B2 (en) 2014-02-14 2021-05-25 The Regents Of The University Of California Cyclic peroxides as prodrugs for selective delivery of agents
WO2015123595A1 (fr) 2014-02-14 2015-08-20 The Regents Of The University Of California Peroxydes cycliques utilisés en tant que promédicaments pour l'administration sélective d'agents
US11566029B2 (en) 2014-02-21 2023-01-31 Ip2Ipo Innovations Limited Pyrazolo[1,5-a]pyrimidine-5,7-diamine compounds as CDK inhibitors and their therapeutic use
US10927119B2 (en) 2014-02-21 2021-02-23 Ip2Ipo Innovations Limited Pyrazolo[1,5-a]pyrimidine-5,7-diamine compounds as CDK inhibitors and their therapeutic use
US9932344B2 (en) 2014-02-21 2018-04-03 Cancer Research Technology Limited Pyrazolo[1,5-A]pyrimidine-5,7-diamine compounds as CDK inhibitors and their therapeutic use
US10414772B2 (en) 2014-02-21 2019-09-17 Imperial Innovations Limited Pyrazolo[1,5-A]pyrimidine-5,7-diamine compounds as CDK inhibitors and their therapeutic use
EP3122728A4 (fr) * 2014-03-28 2017-10-25 Calitor Sciences, LLC Composés hétéroaryle substitués et leurs méthodes d'utilisation
EP3327006A1 (fr) * 2014-03-28 2018-05-30 Calitor Sciences, LLC Composés d'hétéroaryle substitués et procédés d'utilisation
JP2017510644A (ja) * 2014-03-28 2017-04-13 キャリター・サイエンシーズ・リミテッド・ライアビリティ・カンパニーＣａｌｉｔｏｒ Ｓｃｉｅｎｃｅｓ， Ｌｌｃ 置換されたヘテロアリール化合物および使用方法
JP2017510643A (ja) * 2014-03-28 2017-04-13 キャリター・サイエンシーズ・リミテッド・ライアビリティ・カンパニーＣａｌｉｔｏｒ Ｓｃｉｅｎｃｅｓ， Ｌｌｃ 置換されたヘテロアリール化合物および使用方法
WO2017162661A1 (fr) 2016-03-22 2017-09-28 Bayer Pharma Aktiengesellschaft 1h-benzo[de]isoquinoléine-1,3(2h)-diones
US11857552B2 (en) 2017-09-20 2024-01-02 Carrick Therapeutics Limited 4-[[(7-aminopyrazolo[1,5-a]pyrimidin-5-yl)amino]methyl]piperidin-3-ol compounds as CDK inhibitors
CN109096152A (zh) * 2018-07-31 2018-12-28 乐平市赛复乐医药化工有限公司 一种间甲磺酰胺基苯胺的制备方法
CN109096152B (zh) * 2018-07-31 2021-01-08 乐平市赛复乐医药化工有限公司 一种间甲磺酰胺基苯胺的制备方法

Similar Documents

Publication Publication Date Title
WO2012059932A1 (fr) Dérivés de 2,4-diaminopyrimidine en tant qu'inhibiteurs de protéine kinases
JP6047184B2 (ja) トリアジン、ピリミジン、及びピリジン類似体、並びに、治療薬及び診断プローブとしてのそれらの使用
TWI675028B (zh) 做為週期素依賴型激酶（ｃｄｋ）抑制劑之2-ｈ-吲唑衍生物及其醫療用途
CN108368057B (zh) 作为erk抑制剂的吡唑并稠合的杂环化合物
JP6673920B2 (ja) Ｐａｒｇ阻害化合物
JP5188988B2 (ja) ベンゾアゾール誘導体、組成物、及びオーロラキナーゼ阻害剤としての使用方法
AU2013366513B2 (en) Novel benzimidazole derivatives as kinase inhibitors
JP5078016B2 (ja) 医薬化合物
AU2005322085B2 (en) [1H-pyrazolo[3, 4-d]pyrimidin-4-yl]-piperidine or -piperazine compounds as serine-threonine kinase modulators (p70S6K, Atk1 and Atk2) for the treatment of immunological, inflammatory and proliferative diseases
ES2375151T3 (es) Derivados de bencimidazol sustituidos con pirimidina como inhibidores de prote�?na cinasa.
JP5736171B2 (ja) チアゾロピリミジンｐｉ３ｋ阻害剤化合物および使用方法
CN103781780B (zh) 作为jak抑制剂的杂环基嘧啶类似物
JP2012519678A (ja) キナーゼ阻害剤として使用されるピロロピリミジン
AU2006283592A1 (en) Pyrazolopyridine and pyrazolopyrimidine compounds useful as kinase enzymes modulators
WO2009122180A1 (fr) Dérivés de pyrimidine capables d’inhiber une ou plusieurs kinases
KR20110082189A (ko) 아밀로이드 베타의 조절제
CA2587427A1 (fr) Inhibiteurs de kinase
US20100035870A1 (en) Pyrimidin-4-yl-3, 4-Dihydro-2H-Pyrrolo[1,2A] Pyrazin-1-one Compounds
JP2023027203A (ja) ピリミジン化合物及びその医薬用途
JP5508257B2 (ja) アリールアミドピリミドン化合物
JP2009527532A (ja) 癌、感染症、炎症性及び自己免疫性疾患の治療及び／又は予防用の２，４−ジアミノピリミジン誘導体
KR20200115583A (ko) Cdk4 및 cdk6 억제제로서의 2h-인다졸 유도체 및 그의 치료 용도
WO2010002933A1 (fr) Composés d'oxindole
US9688662B2 (en) N-(2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-5-yl)-4-quinazolinamine and N-(2,3-dihydro-1H-indol-5-yl)-4-quinazolinamine derivatives as perk inhibitors
JP7036939B2 (ja) 癌細胞の成長抑制効果を示す新規なピリミジン誘導体及びそれを含む薬剤学的組成物

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10803393

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 10803393

Country of ref document: EP

Kind code of ref document: A1